The essential action is to confirm that the patient has an ST-elevation myocardial infarction (STEMI) on a 12-lead ECG and that primary percutaneous coronary intervention (PCI) cannot be delivered within 120 minutes of first medical contact. Fibrinolysis is a time-critical substitute for mechanical reperfusion, not a default treatment for all acute coronary syndrome. If either condition fails, the drug is the wrong tool and the risk of intracranial hemorrhage or major bleeding rises without a matching benefit.
This article is general educational information, not a diagnosis or treatment plan. Protocols differ by region, hospital capability, and patient factors. Always follow your local cardiology and emergency medicine guidelines, and involve a qualified clinician before administering any fibrinolytic agent.
The Reperfusion Decision Turns on ECG Findings, Not Troponin Alone
The first branch point in acute coronary syndrome is whether the patient has persistent ST-segment elevation or an equivalent pattern on a 12-lead ECG. According to the American College of Cardiology and American Heart Association STEMI guideline, fibrinolysis is indicated when ST elevation is present in at least two contiguous leads, or when there is a new left bundle branch block with ischemic symptoms. A rising troponin confirms myocardial injury but does not by itself justify a fibrinolytic drug.
Time matters more than almost any other variable. The benefit of fibrinolysis falls sharply after the first 2 to 3 hours of symptom onset, and the drug is generally not recommended beyond 12 hours in patients who are asymptomatic and stable. That window is measured from symptom onset, not from arrival at the emergency department. A patient who waited six hours at home has already lost half the high-benefit period.
Equivalents to ST elevation include posterior MI patterns, which show ST depression in V1βV3 with tall R waves, and certain presentations of acute left bundle branch block. These patterns are easy to miss on a quick read. If there is any doubt, get an immediate cardiology or emergency physician over-read rather than treating on a single interpreter's impression.
A normal or nondiagnostic ECG in a patient with chest pain does not support fibrinolysis. Neither does ST depression alone, which points toward non-ST-elevation ACS and a different treatment pathway. The distinction is the single most common reason a fibrinolytic is given inappropriately in retrospective reviews of emergency practice.
Primary PCI Within 120 Minutes Overrides the Drug Every Time
When a PCI-capable center can achieve door-to-balloon or first-medical-contact-to-device time within 120 minutes, mechanical reperfusion is preferred over fibrinolysis. The 120-minute figure appears in both the ACC/AHA STEMI guideline and the European Society of Cardiology STEMI guideline. It is a system-level target, not a promise that every patient will meet it.
That 120-minute number deserves a concrete translation. If the nearest PCI center is 90 minutes away by ground ambulance and the catheterization lab needs 30 minutes to prepare, the projected device time is 120 minutes β right at the threshold. Any additional delay, such as weather, traffic, or a busy lab, pushes the patient past the cutoff. In that scenario, fibrinolysis becomes reasonable if there are no contraindications.
Transfer distance is not the only determinant. A rural hospital with no on-site PCI but a functioning helicopter service may meet the window even from 150 miles away. Conversely, an urban hospital five miles from a PCI center can miss the window if the lab is occupied by another case. The decision needs the projected time to device, not the distance on a map.
Systems that track first-medical-contact-to-device time tend to outperform those that track only door-to-balloon time. The first metric captures the prehospital delay, which is often the largest single contributor to lost time. Ask the receiving team for the projected device time in writing or by radio before committing to a plan.
Contraindications Must Be Screened Before the Vial Is Opened
Absolute contraindications to fibrinolysis include any prior intracranial hemorrhage, known structural cerebral vascular lesion such as an arteriovenous malformation, known malignant intracranial neoplasm, ischemic stroke within 3 months, suspected aortic dissection, active bleeding or bleeding diathesis, and significant closed-head or facial trauma within 3 months. The ACC/AHA and ESC guidelines list these consistently, and they are not modifiable in the moment.
Relative contraindications carry more nuance. These include a history of chronic, severe, poorly controlled hypertension, severe uncontrolled hypertension on presentation (systolic above 180 mm Hg or diastolic above 110 mm Hg), history of ischemic stroke more than 3 months earlier, dementia, traumatic or prolonged cardiopulmonary resuscitation, major surgery within 3 weeks, recent internal bleeding within 2 to 4 weeks, and pregnancy. A relative contraindication does not forbid the drug, but it shifts the risk-benefit calculation toward transfer for PCI if time allows.
Age deserves separate mention because it alters the arithmetic. Patients over 75 have a higher baseline risk of intracranial hemorrhage with fibrinolytic therapy, and the absolute benefit is smaller in older adults with more comorbidity. That does not mean the drug is withheld automatically, but the threshold for transfer to PCI should be lower in this group. The ESC guideline specifically flags this age group for cautious decision-making.
Screening has to happen fast, and it has to be documented. A structured checklist read aloud to the team before administration catches many near-misses. Verbal confirmation from the patient or family about prior stroke, recent surgery, and current anticoagulant use is part of that screen. If the history is unobtainable, treat the uncertainty as a reason to favor transfer when the window permits.
Door-to-Needle Time Should Stay Under 30 Minutes Once the Decision Is Made
Once fibrinolysis is chosen, the ACC/AHA guideline sets a door-to-needle target of 30 minutes or less. That target applies to patients who present to a hospital and are treated on site. The clinical benefit of the drug decays with each minute of delay in the same way it does for PCI, though the mechanism is different: earlier lysis limits infarct size and preserves left ventricular function.
Reaching the 30-minute target typically requires a pre-made kit, a standing order set, and a nurse empowered to start preparation once the physician signs. Hospitals that hit the target reliably usually have the drug stocked in the emergency department rather than the pharmacy. A pharmacy pull that takes 15 minutes can consume half the window on its own.
Weight-based dosing is the standard, and the specific agent matters. Tenecteplase is given as a single intravenous bolus adjusted for weight, which makes it faster to administer than an infusion-based regimen. Streptokinase and alteplase have different dosing and infusion schedules. The choice depends on formulary, cost, and local protocol, and it should not be improvised at the bedside.
If the 30-minute target is being missed repeatedly, the fix is usually structural rather than motivational. Measure the interval from arrival to ECG, ECG to decision, and decision to drug. The bottleneck is almost always one of those three segments, and it is usually identifiable from a small chart review. Feedback to the team on the measured intervals tends to shorten them.
Adjunctive Antithrombotic Therapy Follows the Fibrinolytic, Not the Reverse
When a fibrinolytic is given, adjunctive antiplatelet and anticoagulant therapy is part of the same package. The ACC/AHA guideline recommends aspirin plus a P2Y12 inhibitor, with clopidogrel as the usual choice in the fibrinolytic setting because of its established evidence base. Ticagrelor and prasugrel are generally reserved for the PCI pathway, and prasugrel is contraindicated in patients with a history of stroke or transient ischemic attack.
Anticoagulation with unfractionated heparin, enoxaparin, or fondaparinux depends on the fibrinolytic agent and the patient's renal function. Enoxaparin dosing requires adjustment in renal impairment, and fondaparinux is contraindicated in patients with severe renal dysfunction. These details are easy to overlook in the rush, and they matter because bleeding risk compounds when doses are wrong.
The sequencing matters. Giving the antiplatelet and anticoagulant before the fibrinolytic is confirmed as the plan can leave the patient anticoagulated if the decision reverses. In practice, most protocols load aspirin early and hold the P2Y12 inhibitor until the reperfusion strategy is settled. That small pause costs little and prevents a stranded anticoagulated patient who then needs urgent transfer.
Antithrombotic choice also interacts with the contraindication screen. A patient on a direct oral anticoagulant taken within the last 24 to 48 hours has impaired clotting capacity, which raises bleeding risk with a fibrinolytic. In that situation, transfer for PCI is usually the safer path if time allows. Document the last dose and the drug name.
Failed Reperfusion Demands Rescue PCI, and the Clock Restarts
Fibrinolysis fails in a meaningful proportion of patients, and the signs appear within 60 to 90 minutes. The classic markers are persistent chest pain, less than 50 percent resolution of ST elevation on repeat ECG, and hemodynamic instability. When those signs are present, rescue PCI is indicated, and it should not wait for a repeat troponin.
The 50-percent ST resolution threshold is a specific, testable criterion. A 12-lead ECG repeated 60 to 90 minutes after the drug is the standard assessment tool. If ST elevation has fallen by less than half, the fibrinolytic did not achieve reperfusion. That finding is the trigger for urgent transfer, not for a second dose of the same drug.
Routine immediate angiography after fibrinolysis is not recommended for patients who appear to have reperfused. The ESC guideline supports a pharmacoinvasive strategy, in which patients are transferred for angiography within 2 to 24 hours after successful lysis. That schedule balances the benefit of an invasive assessment against the risk of bleeding during the lytic state.
A failed fibrinolytic is a time-critical emergency in its own right. The patient has now received a bleeding-risk drug and still has an occluded artery. Rescue PCI should proceed even if the projected time exceeds the original 120-minute threshold, because the alternative is an ongoing infarction. Notify the receiving center that this is a rescue case so the lab can prioritize it.
Prehospital Fibrinolysis Follows a Different Rule Set
Prehospital fibrinolysis is used in some systems where transport times to PCI are long and a physician-staffed or trained paramedic team can administer the drug. The ESC guideline supports this approach in systems with proven capability, but it is not a universal standard. The United States relies far less on prehospital lysis than parts of Europe, largely because of the density of PCI centers.
The evidence base for prehospital fibrinolysis comes largely from European trials and registry data, and the results depend heavily on system design. A system with 12-lead ECG transmission, remote physician oversight, and short response times can deliver the drug faster than an in-hospital pathway. A system without those features is more likely to give the drug to the wrong patient or miss the PCI window.
Prehospital teams need a clear bypass protocol. If the projected PCI time is within 120 minutes, the ambulance should bypass the local hospital and go straight to the catheterization lab. The drug is reserved for the cases where that bypass would exceed the window. Ambiguity in the protocol tends to produce both overtreatment and undertreatment.
Rural and remote settings are where the trade-off is sharpest. A patient 200 miles from a PCI center with a 3-hour transport time has a genuine case for prehospital lysis if the ECG is diagnostic and no contraindications exist. A patient 30 miles out does not, even if the ambulance is staffed with a capable team. The distance threshold should be written into the protocol.
Transfer Decisions Need a Written Time Estimate, Not a Verbal Guess
The transfer decision is where most reperfusion errors originate. A verbal estimate of "about an hour" from a transfer center is not a projected device time. The number that matters is the sum of ground or air transport time, lab activation time, and any known delays. Getting that number in writing forces the sending and receiving teams to align on the same arithmetic.
The table below lays out how the projected device time changes with common variables. It shows why the same distance can produce different decisions on different days.
| Scenario | Transport time | Lab prep time | Projected device time | Preferred strategy |
|---|---|---|---|---|
| Urban hospital, lab free | 25 min | 20 min | 45 min | Primary PCI |
| Urban hospital, lab occupied | 25 min | 70 min | 95 min | Primary PCI with priority activation |
| Suburban hospital | 60 min | 30 min | 90 min | Primary PCI |
| Rural hospital, ground | 100 min | 30 min | 130 min | Fibrinolysis if eligible |
| Rural hospital, air | 45 min | 30 min | 75 min | Primary PCI |
| Remote hospital, air unavailable | 180 min | 30 min | 210 min | Fibrinolysis if eligible |
The table makes one point plain. Transfer time alone does not decide the strategy; the lab activation interval can push a short transfer past the threshold. A receiving center with a slow lab call-in process can defeat an otherwise adequate PCI window. Ask for the activation time as part of the estimate, not just the drive time.
A written estimate also protects the team if the outcome is adverse. If the record shows a documented projected device time of 130 minutes and a contraindication-free patient, the decision to give a fibrinolytic is defensible. A vague verbal estimate in the chart does not provide that protection.
Documentation and Audit Close the Loop on Every Fibrinolytic Decision
Every fibrinolytic administration should generate a record that captures the ECG finding, the projected PCI time, the contraindication screen, the agent and dose, and the door-to-needle interval. That record serves clinical, quality, and medico-legal purposes at once. Missing elements are the most common finding in case reviews of adverse lytic outcomes.
The door-to-needle interval is the single most useful audit metric. A hospital that tracks it monthly and feeds the results back to the emergency team usually sees improvement within a few quarters. The same is true for the proportion of patients who receive a fibrinolytic despite a documented PCI window under 120 minutes, which should be near zero.
The contraindication screen should be documented in a structured format, not as a narrative note. A checklist with each absolute and relative contraindication listed and marked is faster to complete and easier to audit. It also forces the team to consider each item rather than relying on memory.
Case review of every fibrinolytic, whether the outcome was good or bad, is standard practice in high-performing systems. A good outcome does not mean the decision was correct. A good outcome with an inappropriately administered drug is still a system failure and should be reviewed as such.
FAQ
What if the ECG is ambiguous but the patient looks critically ill?
Treat the ambiguity as a reason to get an immediate over-read from a cardiologist or emergency physician before giving the drug. A critically ill patient with an unclear ECG may have a different diagnosis entirely, such as aortic dissection or pulmonary embolism, where a fibrinolytic could be catastrophic. If the over-read cannot be obtained quickly and the patient is unstable, transfer for PCI is usually the safer path. The drug should not be the default for diagnostic uncertainty.
Can a patient on a direct oral anticoagulant still receive a fibrinolytic?
Generally, no, if the last dose was within 24 to 48 hours, depending on the agent and renal function. The impaired clotting capacity raises the intracranial hemorrhage risk substantially. Transfer for PCI should be pursued if the projected device time is acceptable. If transfer is impossible and the patient is deteriorating, the decision requires senior cardiology input, not a protocol default. Document the last dose, the drug name, and the renal function.
Is fibrinolysis ever appropriate beyond 12 hours after symptom onset?
It is not recommended in patients who are asymptomatic and hemodynamically stable beyond 12 hours. The high-benefit window has closed, and the bleeding risk remains. An occasional exception exists for patients with ongoing ischemic symptoms and persistent ST elevation, but that decision belongs to a cardiologist. The default answer is no, and the reasoning should be documented.
How does prehospital fibrinolysis compare with immediate transfer in a rural system?
It depends on the projected device time, not the distance. If the receiving PCI center can be reached within 120 minutes of first medical contact, immediate transfer is preferred. Beyond that threshold, prehospital lysis by a trained team with 12-lead transmission and remote oversight can shorten reperfusion time. Systems without those features should not attempt prehospital lysis.
What is a pharmacoinvasive strategy, and when does it apply?
A pharmacoinvasive strategy means giving a fibrinolytic and then transferring the patient for angiography within 2 to 24 hours, even if the drug appears to have worked. The ESC guideline supports this approach for patients who receive lysis in settings without immediate PCI access. It combines the speed of lysis with the definitive assessment of angiography. It is not the same as rescue PCI, which is triggered by signs of failed reperfusion.
Does a normal troponin rule out the need for fibrinolysis?
No. Troponin confirms myocardial injury but does not distinguish STEMI from non-STEMI, and it can be normal very early after symptom onset. The decision rests on the ECG and the projected PCI time, not on the troponin value. A normal troponin in a patient with diagnostic ST elevation does not delay reperfusion. Relying on troponin to make the call is a common and dangerous error.
How quickly should ST elevation resolve after a successful fibrinolytic?
Less than 50 percent resolution at 60 to 90 minutes suggests failed reperfusion and should trigger rescue PCI. Greater than 50 percent resolution, along with symptom relief and hemodynamic stability, suggests success. Even with success, the patient should be transferred for angiography within 2 to 24 hours under a pharmacoinvasive strategy. The repeat ECG is the key test, not the patient's subjective report.
What is the single most common system failure in fibrinolytic use?
Giving the drug to a patient who had a PCI window under 120 minutes is the most common avoidable error in retrospective reviews. It usually stems from a verbal transfer estimate that was never written down or a lab activation delay that was not factored in. The fix is a documented projected device time and a structured contraindication screen. Audit of every case closes the loop.
This article is general educational information about reperfusion decision-making in acute coronary syndrome. It is not a diagnosis, treatment plan, or substitute for clinical judgment. Fibrinolytic protocols vary by jurisdiction, hospital capability, and guideline version, so confirm the current standard with your local cardiology service and institutional protocol before acting. For immediate danger or a patient in crisis, contact local emergency services without delay.